What Is Orforglipron?

1. Why a Small Molecule Changes the Rules

Every GLP-1 drug before orforglipron was a peptide: a chain of amino acids that stomach acid and gut enzymes break down. That is why semaglutide, tirzepatide, and liraglutide are injected, and why the semaglutide tablet (Rybelsus) needs an absorption enhancer (SNAC), an empty stomach, a 4 oz water limit, and a 30-minute wait to get 0.4% to 1% of the dose into the blood.

Orforglipron is a conventional drug molecule that binds the same receptor. It survives digestion on its own, so the label reports 77% absolute bioavailability, a peak 4 to 8 hours after the dose, and steady state after about a week of daily dosing. With food, exposure fell 19% in the label’s study and about 18% to 24% in the published food-effect trial, which the label calls not clinically relevant. The instruction is one line: once daily, with or without food, swallow whole.

The trade-off is metabolism. Peptides are cleared by proteolysis and barely interact with other drugs. Orforglipron is metabolised by CYP3A4, so the label caps the dose at 9 mg with strong CYP3A4 inhibitors, says to avoid strong inducers, and limits simvastatin to 20 mg a day. It also delays gastric emptying like every GLP-1 agonist, with the usual caution about oral medicines with a narrow therapeutic index.

2. Weight Loss: ATTAIN-1 and ATTAIN-2

For scale, semaglutide 2.4 mg produced 14.9% in STEP 1 and tirzepatide 15 mg 20.9% in SURMOUNT-1, both injected and both in separate trials. An oral semaglutide 25 mg tablet produced 13.6% in OASIS 4. Orforglipron sits below those on weight, and the trade is the tablet with no rules.

A third trial tested the tablet as a step-down. In the phase 3b ATTAIN-MAINTAIN trial, 376 people who had already lost weight on tirzepatide or semaglutide injections in SURMOUNT-5 were switched to orforglipron or placebo for 52 weeks. Those coming off tirzepatide kept 74.7% of their earlier weight loss on orforglipron versus 49.2% on placebo; those coming off semaglutide kept 79.3% versus 37.6%. The trial had no arm that stayed on the injection and lasted one year (Aronne et al., Nat Med 2026).

3. Blood Sugar: ACHIEVE-1 and ACHIEVE-3

ACHIEVE-1 was monotherapy in 559 adults with early type 2 diabetes: from a baseline HbA1c of 8.0%, the three doses (3, 12, and 36 mg) lowered it by 1.24, 1.47, and 1.48 percentage points over 40 weeks against 0.41 on placebo, with weight loss of 4.5%, 5.8%, and 7.6% against 1.7%.

ACHIEVE-3 is the trial that matters most for the oral question, because it compared the two oral GLP-1 agonists directly in 1,698 adults with type 2 diabetes over 52 weeks.

HbA1c, safety and pulse figures are from the Lancet paper (treatment-regimen estimand); the weight figures are Lilly’s on-treatment efficacy-estimand results (Lilly, June 2026). The trial was open label.

Orforglipron won on both endpoints and paid for it in tolerability. The Foundayo vs Rybelsus page has the charts and the caveats, including that ACHIEVE-3 is a diabetes trial and Foundayo is not approved for diabetes in the US. Lilly has submitted the US type 2 diabetes application (Lilly Q2 2026 results), and the UK’s MHRA authorised orforglipron on August 10, 2026 for weight management and for glycaemic control in type 2 diabetes (MHRA).

ACHIEVE-2 and ACHIEVE-5

Two more diabetes trials were published in 2026. In ACHIEVE-2, 962 adults on metformin received orforglipron 3, 12, or 36 mg or dapagliflozin 10 mg for 40 weeks, open label. HbA1c fell 1.23, 1.50, and 1.56 percentage points versus 0.81 on dapagliflozin, so every dose was non-inferior and then superior; gastrointestinal events were 46% to 54% versus 12% (Welch et al., Lancet 2026). In ACHIEVE-5, 546 adults on titrated insulin glargine added orforglipron or placebo for 40 weeks: HbA1c fell 1.58, 1.88, and 1.82 points versus 0.79, weight changed −2.6%, −4.8%, and −5.4% versus +0.2%, and clinically significant hypoglycaemia did not increase (Giorgino et al., JAMA 2026).

Cardiovascular Safety: ACHIEVE-4

ACHIEVE-4 randomised 2,749 adults with type 2 diabetes and established cardiovascular or chronic kidney disease to orforglipron (up to the 36 mg trial dose, equivalent to the 17.2 mg tablet) or insulin glargine, open label, over a median 2 years. Major cardiovascular events (cardiovascular death, heart attack, stroke, or hospitalisation for unstable angina) occurred in 4.2% versus 5.0%, hazard ratio 0.84 (95% CI 0.59 to 1.20), which met the prespecified non-inferiority margin of 1.8. It shows cardiovascular safety, not benefit. Gastrointestinal events were 62.1% versus 14.2%, and clinically significant or severe hypoglycaemia 6.8% versus 19.2% (Klein et al., Lancet 2026).

4. Trial Doses and Tablet Strengths

The ATTAIN papers report arms of 6, 12, and 36 mg, and the ACHIEVE papers 3, 12, and 36 mg. The Foundayo label lists tablets of 0.8, 2.5, 5.5, 9, 14.5, and 17.2 mg, with 17.2 mg the maximum. The two sets describe the same treatment: the commercial tablet is a different formulation labelled by a different dose convention, and Lilly’s later analyses report the ATTAIN arms as 5.5, 9, and 17.2 mg. The label itself notes that most of its pharmacokinetic data were generated with the investigational formulation. Lilly’s June 2026 diabetes results use the same convention, with the 3 mg arm reported as 2.5 mg (Lilly, June 2026). When reading a paper against the box, 3 mg corresponds to 2.5 mg, 6 to 5.5, 12 to 9, and 36 to 17.2.

5. Where the Brand Page Takes Over

The molecule is the same whatever it is called; the label is Foundayo’s. The Foundayo page covers what was approved, the 30-day dose ladder, the missed-dose rule, the CYP3A4 dosage modification, and the safety sections including how the class boxed warning is worded for a drug that is not active in rodents. For the route question in general, see oral vs injectable GLP-1. For the log, a daily tablet is the simplest entry there is: product, date, milligrams.

6. Orforglipron FAQ

• Is orforglipron a peptide?

  No. Semaglutide, tirzepatide, and liraglutide are peptides, chains of amino acids that the gut breaks down, which is why they are injected or need an absorption enhancer as a tablet. Orforglipron is a conventional small-molecule drug of about 900 daltons that binds the GLP-1 receptor and survives digestion on its own.

• How much weight loss does orforglipron produce?

  In ATTAIN-1, adults with obesity and no diabetes lost 7.5%, 8.4%, and 11.2% of body weight on the three doses over 72 weeks, against 2.1% on placebo. In ATTAIN-2, adults with obesity and type 2 diabetes lost 5.1%, 7.0%, and 9.6% against 2.5%.

• Is orforglipron better than oral semaglutide?

  In ACHIEVE-3, the only direct trial, orforglipron 12 and 36 mg lowered HbA1c by 1.71 and 1.91 percentage points over 52 weeks against 1.23 and 1.47 for semaglutide 7 and 14 mg, with weight loss of 6.7% and 9.2% versus 3.7% and 5.3% in Lilly's on-treatment (efficacy estimand) analysis. Gastrointestinal events were 58% to 59% versus 37% to 45%, and discontinuations for adverse events 9% to 10% versus 4% to 5%. The Foundayo vs Rybelsus page has the detail.

• Why do the trial doses and the tablet strengths not match?

  The ATTAIN papers report 6, 12, and 36 mg arms and the ACHIEVE papers 3, 12, and 36 mg. The marketed equivalents are 5.5, 9, and 17.2 mg, and 2.5 mg for the 3 mg arm. The commercial tablet is a different formulation labelled by a different dose convention, and Lilly's later analyses report the same trial arms under the marketed numbers. The dose steps in the label are 0.8, 2.5, 5.5, 9, 14.5, and 17.2 mg.

• What is the difference between orforglipron and Foundayo?

  Orforglipron is the molecule; Foundayo is Lilly's brand of it, approved by the FDA on April 1, 2026 for weight reduction in adults. In the US it is not approved for type 2 diabetes, though Lilly has submitted that application; the UK authorised it in August 2026 for weight management and type 2 diabetes. The Foundayo page covers the label: dosing, missed doses, interactions, and safety.

7. Sources